AIM ImmunoTech Inc.
AIM
$9.21
$0.9110.96%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 146.00K | 170.00K | 190.00K | 201.00K | 193.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.00K | 170.00K | 190.00K | 201.00K | 193.00K |
| Cost of Revenue | 33.00K | 31.00K | 36.00K | 58.00K | 50.00K |
| Gross Profit | 113.00K | 139.00K | 154.00K | 143.00K | 143.00K |
| SG&A Expenses | 12.64M | 13.90M | 20.54M | 22.90M | 22.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.80M | 19.94M | 28.11M | 31.79M | 33.55M |
| Operating Income | -17.66M | -19.77M | -27.92M | -31.59M | -33.36M |
| Income Before Tax | -15.21M | -17.32M | -23.93M | -28.05M | -31.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.21 | -17.32 | -23.93 | -28.05 | -31.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.21M | -17.32M | -23.93M | -28.05M | -31.12M |
| EBIT | -17.66M | -19.77M | -27.92M | -31.59M | -33.36M |
| EBITDA | -17.41M | -19.53M | -27.68M | -31.36M | -33.11M |
| EPS Basic | -24.72 | -31.28 | -47.85 | -57.60 | -64.33 |
| Normalized Basic EPS | -15.49 | -19.45 | -30.51 | -35.95 | -40.14 |
| EPS Diluted | -24.72 | -31.28 | -47.85 | -57.60 | -64.33 |
| Normalized Diluted EPS | -15.49 | -19.45 | -30.51 | -35.95 | -40.14 |
| Average Basic Shares Outstanding | 247.31M | 226.23M | 210.95M | 201.82M | 197.35M |
| Average Diluted Shares Outstanding | 247.31M | 226.23M | 210.95M | 201.82M | 197.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |